Меню
Идёт набор NCT06753773

Red Light Therapy: Short-term Choroidal and Retinal Changes

Без фазы С лечением Myopia

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Repeated Low-Level Red-Light.
Кому может быть актуально
Состояния в реестре: Myopia. Базовые параметры: 18 лет — 40 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Гонконг
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

The Short-term Impact of Different Types of Red Light Therapy on Choroid and Retina

Обзор

This research project is a prospective, randomized controlled trial designed to assess the short-term effects of varied red light therapies on the choroidal and retinal structures in adult myopes. The primary objective is to determine which specific retinal regions or cells are primarily affected by short-term repeated low-level red-light (RLRL) therapy, potentially inducing choroidal thickening. The secondary objective is to assess the safety of different types of red light therapy in adult myopes. The study will enroll 45 myopic adults aged 18-40 years old as participates. They will be randomly assigned into three RLRL groups: small circle (d=0.30mm), medium circle (d=0.50mm), and annular groups (an inner diameter of 0.50 mm and an outer diameter of 0.70mm) without disclosure of their specific group to maintain study blinding. The groups are differentiated by the size and shape of the light spots formed on the retina but with the same power (0.15 mW with a 4 mm pupil size). The Eyerising Myopia Management Device, modified for this study, will be used to administer RLRL with three different spot patterns, adhering to safety standards to minimize risk and ensure participant safety. Before the treatment, baseline data will be collected from each participant. Baseline assessments will consist of demographics information, visual acuity checks, axial length measurements, subjective refraction, slit-lamp examinations, adaptive optics imaging, optical coherence tomography and angiography (OCT \& OCTA), posterior blood flowgraphy, electroretinography (ERG), and the Flicker-plus test. Then participants will undergo daily treatments for 14 days, using the therapy settings of the group to which they have been assigned. The treatment will last for 3 minutes twice a day, with a minimal interval of 4 hours. During the 14-day study period, participants will undergo daily assessments by a series of ophthalmic examinations. Outcomes measured will track changes in choroidal thickness, electrical activity of the retina, axial length, and best corrected visual acuity, alongside other image reports such as adaptive optics imaging, posterior blood flowgraphy and OCT \& OCTA scans. This study addresses the gaps in understanding how RLRL therapy affects myopia and aims to identify the retina's high-response areas to red light. By doing so, it hopes to minimize unnecessary exposure and potential damage, enhancing the safety and effectiveness of the therapy.

Вмешательства

  • Устройство Repeated Low-Level Red-Light
    All participants will receive a video guide of the Repeated Low-Level Red-Light device. Eligible subjects will receive daily treatment for 14 days, with each treatment lasting for 3 minutes twice a day, with a minimal interval of 4 hours.

Первичные конечные точки

  • Change in choroidal thickness measured by OCT [Срок оценки: Choroidal thickness will be measured every day from enrollment to the end of treatment at 2 weeks.]
Вторичные конечные точки (7)
  • Change in electrical activity of the retina measured by ERG [Срок оценки: ERG will be carried out on the 7th and 14th days of the study]
  • Change in axial length (AL) measured by IOL Master [Срок оценки: AL will be taken every day from enrollment to the end of treatment at 2 weeks.]
  • Change in best corrected visual acuity (BCVA) [Срок оценки: BCVA will be taken every day from enrollment to the end of treatment at 2 weeks.]
  • Change in adaptive optics imaging [Срок оценки: Adaptive optics imaging assessment will be carried out on the 7th and 14th days of the study.]
  • Change in optical coherence tomography angiography (OCTA) scan [Срок оценки: OCTA assessment will be taken every day from enrollment to the end of treatment at 2 weeks.]
  • Change in posterior blood flowgraphy [Срок оценки: The posterior blood flowgraphy will be taken every day from enrollment to the end of treatment at 2 weeks.]
  • Change in flicker-plus test [Срок оценки: Flicker-plus test will be carried out on the 7th and 14th days of the study]

Критерии участия

Критерии включения

  • Age: 18 to 40 years.
  • Myopic spherical equivalent refraction (SER) between -1.00D to -6.00D in both eyes.
  • Best corrected visual acuity (BCVA): 20/20 or greater.
  • Informed consent for participation.

Критерии исключения

  • Anisometropia greater than 1.50D.
  • Ophthalmic diseases other than refractive errors, including but not limited to strabismus and binocular vision abnormalities in either eye.
  • Systemic diseases (e.g., endocrine, cardiac diseases) and developmental abnormalities.
  • Inability to attend regular follow up assessment.
  • Undergo RLRL therapy in the past 6 months
  • Contraindications to RLRL therapy.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Тройное слепое
Основная цель
Лечение

Центры проведения

Гонконг · 1 центр
  • The Hong Kong Polytechnic University — Гонконг

Идентификаторы

NCT: NCT06753773 · HSEARS20240715002

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗